Aeglea Bio Therapeutics (NASDAQ:AGLE) Downgraded to Buy at ValuEngine

ValuEngine downgraded shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a strong-buy rating to a buy rating in a report released on Tuesday morning, ValuEngine reports.

Other equities analysts also recently issued reports about the stock. BidaskClub raised shares of Aeglea Bio Therapeutics from a sell rating to a hold rating in a report on Thursday, September 12th. Zacks Investment Research downgraded shares of Aeglea Bio Therapeutics from a hold rating to a sell rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $14.33.

Shares of AGLE traded up $0.30 on Tuesday, reaching $8.30. The company’s stock had a trading volume of 174,356 shares, compared to its average volume of 139,190. Aeglea Bio Therapeutics has a twelve month low of $5.99 and a twelve month high of $9.45. The stock has a market capitalization of $226.96 million, a PE ratio of -3.90 and a beta of 1.07. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $7.74 and a 200-day moving average of $7.39.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.12). As a group, equities analysts anticipate that Aeglea Bio Therapeutics will post -2.51 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC bought a new stake in Aeglea Bio Therapeutics in the second quarter worth about $68,000. Deltec Asset Management LLC grew its holdings in Aeglea Bio Therapeutics by 25.1% during the second quarter. Deltec Asset Management LLC now owns 47,864 shares of the biotechnology company’s stock valued at $328,000 after purchasing an additional 9,600 shares during the period. Wells Fargo & Company MN grew its holdings in Aeglea Bio Therapeutics by 51.3% during the second quarter. Wells Fargo & Company MN now owns 61,235 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 20,772 shares during the period. JPMorgan Chase & Co. grew its holdings in Aeglea Bio Therapeutics by 700.9% during the second quarter. JPMorgan Chase & Co. now owns 53,450 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 46,776 shares during the period. Finally, Aisling Capital Management LP increased its position in Aeglea Bio Therapeutics by 5.8% in the second quarter. Aisling Capital Management LP now owns 1,291,151 shares of the biotechnology company’s stock worth $8,844,000 after buying an additional 70,240 shares during the last quarter. 68.37% of the stock is owned by institutional investors.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Featured Story: How Do I Invest in Dividend Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.